ArticleFrontiers in oncology2025
Case Report: Treatment with magnetic nanoparticle-based hyperthermia stabilizes metastatic disease in stage IV primary liver cancer patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bioengineered systems to exploit tumor microenvironment metabolism.Trends in cancer · 2026Review
- Toward oral nanomaterial-based drug delivery systems for hepatocellular carcinoma therapy: evidence mapping, route-specific validation, and translational challenges.Frontiers in pharmacology · 2026Review
- Clinical Translation of Functional Magnetic Nanoparticles for Intracellular Hyperthermia and Cancer Immunotherapy.International journal of nanomedicine · 2026Review
- Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The First-in-Human clinical trial of a novel magnetic nanoparticle-based hyperthermia therapy consisting of iron oxide multicore encapsulated nanoparticles, termed Sarah Nanoparticles (SaNP), administered intravenously before being exposed to alternating magnetic field (AMF) irradiation began enrolment. We report the preliminary results on two patients with advanced primary liver cancer; a 75-year-old man with advanced stage hepatocellular carcinoma and a 69-year-old woman with metastatic cholangiocarcinoma treated with a SaNP dose of 1.8 mg/kg followed by pulsed AMF irradiation for a total duration of 15 min. Toxicity assessment was performed using standard criteria for the grading of adverse events during treatment and after a follow-up period of 30 days. Tumor response was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Both patients tolerated the procedure well without any significant clinical or laboratory toxicities. Magnetic resonance imaging (MRI) analysis revealed accumulation of the SaNP in the tumors followed by clearance from the liver and spleen on T2*-weighted MR imaging. Tumor response as assessed by RECIST 1.1 demonstrated stable disease at the follow-up timepoint. Preliminary analysis of this First-in-Human trial of magnetic nanoparticle-based hyperthermia treatment for patients with advanced cancer demonstrated encouraging results both in terms of efficacy by halting disease progression and toxicity, where no significant side effects occurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.